BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cathomas F, Klaus F, Guetter K, Chung HK, Raja Beharelle A, Spiller TR, Schlegel R, Seifritz E, Hartmann-Riemer MN, Tobler PN, Kaiser S. Increased random exploration in schizophrenia is associated with inflammation. NPJ Schizophr 2021;7:6. [PMID: 33536449 DOI: 10.1038/s41537-020-00133-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Ramos-vera C, Rosa Franco V, Vallejos Saldarriaga J, Serpa Barrientos A. Psychometric Networks and Their Implications for the Treatment and Diagnosis of Psychopathologies. Psychometrics - New Insights [Working Title] 2022. [DOI: 10.5772/intechopen.105404] [Reference Citation Analysis]
2 Lestra V, Romeo B, Martelli C, Benyamina A, Hamdani N. Could CRP be a differential biomarker of illness stages in schizophrenia? A systematic review and meta-analysis. Schizophr Res 2022;246:175-86. [PMID: 35785580 DOI: 10.1016/j.schres.2022.06.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Hauke G, Lohr C. Piloting the Update: The Use of Therapeutic Relationship for Change – A Free Energy Account. Front Psychol 2022;13:842488. [DOI: 10.3389/fpsyg.2022.842488] [Reference Citation Analysis]
4 Purcell JR, Herms EN, Morales J, Hetrick WP, Wisner KM, Brown JW. A review of risky decision-making in psychosis-spectrum disorders. Clin Psychol Rev 2022;91:102112. [PMID: 34990988 DOI: 10.1016/j.cpr.2021.102112] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Costi S, Morris LS, Collins A, Fernandez NF, Patel M, Xie H, Kim-Schulze S, Stern ER, Collins KA, Cathomas F, Parides MK, Whitton AE, Pizzagalli DA, Russo SJ, Murrough JW. Peripheral immune cell reactivity and neural response to reward in patients with depression and anhedonia. Transl Psychiatry 2021;11:565. [PMID: 34741019 DOI: 10.1038/s41398-021-01668-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
6 Klaus F, Guetter K, Schlegel R, Spiller TR, Seifritz E, Cathomas F, Kaiser S. Common and disorder-specific upregulation of the inflammatory markers TRAIL and CCL20 in depression and schizophrenia. Sci Rep 2021;11:19204. [PMID: 34584171 DOI: 10.1038/s41598-021-98769-0] [Reference Citation Analysis]
7 Bavato F, Cathomas F, Klaus F, Gütter K, Barro C, Maceski A, Seifritz E, Kuhle J, Kaiser S, Quednow BB. Altered neuroaxonal integrity in schizophrenia and major depressive disorder assessed with neurofilament light chain in serum. J Psychiatr Res 2021;140:141-8. [PMID: 34116440 DOI: 10.1016/j.jpsychires.2021.05.072] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
8 Boczek T, Mackiewicz J, Sobolczyk M, Wawrzyniak J, Lisek M, Ferenc B, Guo F, Zylinska L. The Role of G Protein-Coupled Receptors (GPCRs) and Calcium Signaling in Schizophrenia. Focus on GPCRs Activated by Neurotransmitters and Chemokines. Cells 2021;10:1228. [PMID: 34067760 DOI: 10.3390/cells10051228] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
9 Cathomas F, Guetter K, Seifritz E, Klaus F, Kaiser S. Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. Sci Rep 2021;11:9992. [PMID: 33976271 DOI: 10.1038/s41598-021-89335-9] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
10 Cathomas F, Klaus F, Guetter K, Seifritz E, Hartmann-riemer MN, Tobler PN, Kaiser S, Kaliuzhna M. Associations Between Negative Symptoms and Effort Discounting in Patients With Schizophrenia and Major Depressive Disorder. Schizophrenia Bulletin Open 2021;2. [DOI: 10.1093/schizbullopen/sgab022] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]